We're sunsetting PodQuest on 2025-07-28. Thank you for your support!
Export Podcast Subscriptions
cover of episode EP 287: Harnessing AI Technologies for Next-Generation Clinical Trials

EP 287: Harnessing AI Technologies for Next-Generation Clinical Trials

2024/6/5
logo of podcast Everyday AI Podcast – An AI and ChatGPT Podcast

Everyday AI Podcast – An AI and ChatGPT Podcast

Shownotes Transcript

Send Everyday AI and Jordan a text message)

Clinical trials can sometimes take years and cost many of millions of dollars. Why is that? And how can AI help bring faster and better outcomes?  Saurabh Jain, Executive Chairman at TrialKey.ai,  joins us to discuss how we can harness AI for clinical trials. Newsletter: Sign up for our free daily newsletter)**More on this Episode: **Episode Page)**Join the discussion: **Ask Jordan and Saurabh questions on AI in clinical trials)**Related Episode: **Ep 107: How AI Turns Clinical Trials into Medical Knowledge)Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineup)Website: YourEverydayAI.com)Email The Show: [email protected])**Connect with Jordan on **LinkedIn)**Topics Covered in This Episode:1. State and Limitations of Traditional Clinical Trials2. Role of Generative AI in Modern Drug Development3. AI in Clinical Trials4. Exploring ChatGPT in Clinical TrialsTimestamps:**01:30 Daily AI news04:20 About Saurabh and TrialKey.ai09:33 ChatGPT transforms unstructured data to structured.10:43 Addressing hallucinations, incomplete datasets, and novel drugs.15:16 Challenges in drug development and commercialization balancing.18:30 Challenges of AI in research investment and focus.24:15 Balancing AI and human ethics in medicine.28:23 AI's potential in clinical trials, despite challenges.**Keywords:**Generative AI, clinical trials, advanced AI, drug discovery, Treatment Market, AI news, Elon Musk, NVIDIA GPU chips, Tesla, XAI, US Treasury, Janet Yellen, Saurabh Jain, Trial Key AI,Large language model, COVID-19, drug development, Jordan Wilson, AI simulations, drug market approval, FDA regulations, GPT technology, chat GPT, AI computer technology, pharmaceutical companies, machine learning, rare diseases, trial design, phase 3 trials, trial success prediction.